Recurrent Verrucous Carcinoma of the Larynx Withdrawn Phase 1 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01332279Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation TherapyTreatment